OY-101

Names

[ CAS No. ]:
41183-02-2

[ Name ]:
OY-101

[Synonym ]:
1-[3-Benzyloxy-4-methoxy-benzyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isochinolin
(+/-)-O-benzyl-laudanine
(+/-)-O-benzyllaudanidine
1-(3-Benzyloxy-4-methoxy-benzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-isochinolin
1-(3-benzyloxy-4-methoxy-benzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinoline
(+/-)-O-Benzyl-laudanin

Biological Activity

[Description]:

OY-101 is an orally active, potent and specific P-glycoprotein (P-gp) inhibitor. OY-101 can sensitize drug-resistant tumors and effectively reverse tumor multidrug resistance. OY-101 is improvements in water-solubility, cytotoxicity, and reversal activity compared to Tetrandrine (HY-13764)[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Membrane Transporter/Ion Channel >> P-glycoprotein

[In Vitro]

OY-101 与Vincristine (HY-N0488A) 对耐药细胞 Eca109/VCR 表现出优异的协同抗癌作用,IC50 为 9.9 ± 1.3 nM< sup>[1]。 OY-101 (0-5 μM) 对 Eca109/VCR 细胞没有显著毒性,并且在 Eca109/VCR 细胞中表现出显着增加的Vincristine (HY-N0488A) 敏感性[1]。 Cell Viability Assay[1] Cell Line: Eca109/VCR cells Concentration: 1.0, 2.5, and 5.0 μM Incubation Time: 48 h Result: Exhibited significantly increased Vincristine sensitization in Eca109/VCR cells, achieving around 3.7, 103.4, and 690.6-fold reversal activity, respectively.

[In Vivo]

OY-101 (30 mg/kg/2 天,灌胃,持续 3 周)增加体内对长春新碱 (HY-N0488A) 的致敏性,且无明显毒性[1]。 OY-101 (静脉给药 (3 mg/kg) 和口服给药 (30 mg/kg);一次) 表现出良好的药代动力学[1]。 Animal Model: Female nude mice (4-5 weeks old, xenograft model bearing P-gp-overexpressing Eca109/VCR cells)[1] Dosage: 30 mg/kg Administration: IG, once every 2 days, for 3 weeks, 1 h before tail vein injection of Vincristine (HY-N0488A) Result: Only co-administration OY-101 with Vincristine can effectively inhibit tumor proliferation in vivo (P < 0.001) and significantly reduce tumor weight. After 3 weeks of treatment, the tumor growth inhibition rate of the OY-101/Vincristine combination was 79.13%, which was significantly lower than that of the single-treatment group and the vehicle group. Animal Model: SD rats (8 week-old, male, 300-400 g)[1] Dosage: 3 mg/kg (IV), 30 mg/kg (PO) Administration: Intravenous and oral administration, once (Pharmacokinetic Analysis) Result: Pharmacokinetic Parameters of OY-101 in male Sprague-Dawley rats[1]. IV (3 mg/kg) PO (30 mg/kg) Tmax (h) 0.17 ± 0.12 0.38 ± 0.18 Cmax (ng/mL) 1573.20 ± 143.97 636.55 ± 355.60 AUC0-t (ng/mL∗h) 2688.45 ± 180.10 2665.45 ± 450.92 t1/2 (h) 8.43 ± 7.83 7.37 ± 4.92 CL/F (L/kg/h) 1.10 ± 0.08 11.16 ± 2.10 Vz/F (L/kg) 12.84 ± 11.33 111.27 ± 56.82 F (%) 7.65 ± 2.15

[References]

[1]. Zeng R, et al. Simplified Derivatives of Tetrandrine as Potent and Specific P-gp Inhibitors to Reverse Multidrug Resistance in Cancer Chemotherapy. J Med Chem. 2023 Mar 23;66(6):4086-4105.  

Chemical & Physical Properties

[ Molecular Formula ]:
C27H31NO4

[ Molecular Weight ]:
433.54

[ Exact Mass ]:
433.22500

[ PSA ]:
40.16000

[ LogP ]:
5.00100

Precursor & DownStream

Precursor

DownStream


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.